CARL ZEISS MEDITEC ADR 1 (AFXA) - Net Assets
Based on the latest financial reports, CARL ZEISS MEDITEC ADR 1 (AFXA) has net assets worth €2.13 Billion EUR (≈ $2.49 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.40 Billion ≈ $3.98 Billion USD) and total liabilities (€1.28 Billion ≈ $1.49 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AFXA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €2.13 Billion |
| % of Total Assets | 62.52% |
| Annual Growth Rate | 1.58% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 5.21 |
CARL ZEISS MEDITEC ADR 1 - Net Assets Trend (2022–2025)
This chart illustrates how CARL ZEISS MEDITEC ADR 1's net assets have evolved over time, based on quarterly financial data. Also explore AFXA current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for CARL ZEISS MEDITEC ADR 1 (2022–2025)
The table below shows the annual net assets of CARL ZEISS MEDITEC ADR 1 from 2022 to 2025. For live valuation and market cap data, see CARL ZEISS MEDITEC ADR 1 (AFXA) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | €2.13 Billion ≈ $2.49 Billion |
+3.46% |
| 2024-09-30 | €2.06 Billion ≈ $2.40 Billion |
-5.36% |
| 2023-09-30 | €2.17 Billion ≈ $2.54 Billion |
+7.03% |
| 2022-09-30 | €2.03 Billion ≈ $2.37 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CARL ZEISS MEDITEC ADR 1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 29.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €1.58 Billion | 74.42% |
| Other Components | €541.39 Million | 25.58% |
| Total Equity | €2.12 Billion | 100.00% |
CARL ZEISS MEDITEC ADR 1 Competitors by Market Cap
The table below lists competitors of CARL ZEISS MEDITEC ADR 1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aker Solutions ASA
OL:AKSO
|
$2.14 Billion |
|
Sinbon Electronics Co Ltd
TW:3023
|
$2.14 Billion |
|
Changchun UP Optotech Co Ltd
SHE:002338
|
$2.14 Billion |
|
CENTRAL PUERTO ADR/1 AP1
F:C3TA
|
$2.14 Billion |
|
NV Bekaert SA
BR:BEKB
|
$2.14 Billion |
|
Shenzhen Agricultural Products Co Ltd
SHE:000061
|
$2.14 Billion |
|
Lucid Group Inc
NASDAQ:LCID
|
$2.14 Billion |
|
Northwest Natural Gas Co
NYSE:NWN
|
$2.14 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CARL ZEISS MEDITEC ADR 1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,041,697,000 to 2,116,506,000, a change of 74,809,000 (3.7%).
- Net income of 141,210,000 contributed positively to equity growth.
- Dividend payments of 52,522,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €141.21 Million | +6.67% |
| Dividends Paid | €52.52 Million | -2.48% |
| Other Changes | €-13.88 Million | -0.66% |
| Total Change | €- | 3.66% |
Book Value vs Market Value Analysis
This analysis compares CARL ZEISS MEDITEC ADR 1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.10x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-09-30 | €22.53 | €26.60 | x |
| 2023-09-30 | €24.14 | €26.60 | x |
| 2024-09-30 | €23.32 | €26.60 | x |
| 2025-09-30 | €24.18 | €26.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CARL ZEISS MEDITEC ADR 1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.67%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.34%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.61x
- Recent ROE (6.67%) is below the historical average (10.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 14.59% | 15.45% | 0.67x | 1.40x | €92.40 Million |
| 2023 | 13.45% | 13.90% | 0.69x | 1.40x | €74.45 Million |
| 2024 | 8.75% | 8.65% | 0.61x | 1.66x | €-25.44 Million |
| 2025 | 6.67% | 6.34% | 0.65x | 1.61x | €-70.44 Million |
Industry Comparison
This section compares CARL ZEISS MEDITEC ADR 1's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $6,017,436,443
- Average return on equity (ROE) among peers: -96.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CARL ZEISS MEDITEC ADR 1 (AFXA) | €2.13 Billion | 14.59% | 0.60x | $2.14 Billion |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $709.04 Million | 17.68% | 0.69x | $2.39 Billion |
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | $2.51 Billion | 34.85% | 1.01x | $16.46 Billion |
| MEDIMI AB AK (79T) | $332.69K | -959.52% | 4.12x | $427.04K |
| TEVANO SYSTEMS HLDGS INC. (7RBA) | $-1.31 Million | 0.00% | 0.00x | $210.67K |
| STEVANATO GROUP SPA O.N. (87N) | $841.66 Million | 15.96% | 0.69x | $831.06 Million |
| Carl Zeiss Meditec AG (AFX) | $797.45 Million | 7.81% | 0.43x | $2.23 Billion |
| Bio-gate AG (BIG1) | $1.55 Million | -51.89% | 1.13x | $5.32 Million |
| COLOPLAST SP.ADR 1/10 DK1 (CBH) | $8.29 Billion | 56.75% | 3.52x | $12.73 Billion |
| ESSILORLUXOTTICA 1/2/O.N. (ESLC) | $41.00 Billion | 5.75% | 0.57x | $93.24 Billion |
About CARL ZEISS MEDITEC ADR 1
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for ret… Read more